Search Results

You are looking at 11 - 20 of 43 items for

  • Author or Editor: Zach Cahill x
  • Refine by Content Type: All x
Clear All Modify Search
Zach Cahill

The growing number of clinical trials the kidney community has enjoyed over the past few years is endangered due to the COVID-19 pandemic. Concerns over the safety of trial participants and investigators are paramount and are leading to rapid changes in the conduct of clinical trials.

The US Food and Drug Administration (FDA) released “Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic” , updated March 27, to provide clarity to the clinical trial community. Considering this guidance and after soliciting reactions from the clinical trial community, the Clinical Trials Transformation Initiative (CTTI) hosted a webinar on March 31 titled “Identifying Best Practices for Conducting Clinical Trials with the New FDA Guidance During the COVID”.

Zach Cahill

ttp _thumb_0.pngThe American Society Nephrology (ASN) is pleased to announce that Raymond C. Harris, MD, FASN , has been selected as the incoming ASN Co-Chair for the Kidney Health Initiative (KHI). Dr. Harris will serve a three-year term, starting in January 2019.  Dr. Harris will succeed Prabir Roy-Chaudhury, MD, PhD, FASN, who has served six years as KHI’s founding co-chair.

Zach Cahill

While dialysis is a life-saving therapy for patients with end stage kidney disease (ESKD), a variety of symptoms occur following treatment that significantly diminishes the quality of life of people living with kidney disease. A 2009 study published in the Clinical Journal of the American Society of Nephrology (CJASN) reported that patients on maintenance dialysis experience 11 unique symptoms. Patients have identified the need to alleviate these symptoms as a key research area, prioritizing it above other health outcomes. Alleviation of these symptoms could result in increased quality of life and better patient-reported outcome measures. Despite the patient demand for new therapies to address these symptoms, no drug or device has been approved by the US Food and Drug Administration (FDA) to date.

Zach Cahill

KHI_Logo-Horizontal-Color_0.jpgThe Advancing American Kidney Health initiative made developing an artificial kidney a national priority. The increased interest, investment, and innovation brought about by this policy highlight the need for new and improved infrastructure to facilitate innovation.

Zach Cahill

ima_thumb.pngIn early December 2018, Prabir Roy-Chaudhury, MD, PhD, FASN, the outgoing American Society of Nephrology Co-Chair for KHI, and Raymond C. Harris, MD, FASN, who began his term as Co-Chair for KHI in 2019, recorded a discussion with ASN Executive Vice-President Tod Ibrahim. This wide-ranging Kidney News podcast included Dr. Roy-Chaudhury’s evaluation of his six-year tenure and an outline of Dr. Harris’ vision for the future.

Zach Cahill

While there are many incentives to invest in rare diseases, well designed clinical trials are critical to getting the new therapies conceived by pharmaceutical companies to the people who need them.  

Primary hyperoxaluria (PH) is a rare genetic kidney disease impacting fewer than 1000 people in the US. While many people with kidney disease are asymptomatic until they progress to kidney failure and can rely on dialysis or a transplant to replace their kidney function, the unique characteristics of PH cause severe symptoms early in life and make common kidney replacement therapies ineffective.

Zach Cahill

The Kidney Health Initiative (KHI) recently released a new website to inform the community about its mission, objectives, and membership. The new site also showcases the publications from completed projects since the formation of KHI in 2012.

For the first time, KHI’s research and recommendations are centralized and accessible to kidney health professionals, researchers, patients, and innovators. The redesigned website highlights:

Zach Cahill

Rare Disease Day on Saturday, February 29, is intended to raise awareness of the thousands of rare diseases and the millions of people who live with them around the world. There are more than 100 rare kidney diseases, most of them without US Food and Drug Administration (FDA) approved therapies. Because of the lack of innovation in novel therapies to treat rare kidney diseases, many people who live with them face the prospect of progressing to kidney failure and enduring dialysis or waiting for a kidney transplant.

Zach Cahill

The Kidney Health Initiative (KHI) hosted its Seventh Annual Stakeholders Meeting May 29-30, in Washington DC. The annual meeting revolved around the theme of “Collaborating for Innovation to Improve Patient Care and Outcomes”. Planning Committee Co-Chairs Paul T. Conway and Mahesh Krishnan, MD, FASN, developed a program that attracted nearly 200 registrants. The “think-tank” style meeting included onstage Q&A with government representatives, presentations from leaders in the kidney community, and member showcases highlighting innovations around the KHI membership.

Zach Cahill

“What I have learned more than anything else, is that if you get talented and committed people from different backgrounds together, then wonderful and impactful things just seem to happen.” Prabir Roy-Chaudhury, MD, PhD, FASN, ASN Co-Chair for the Kidney Health Initiative

KHI is a public private partnership with the US Food and Drug Administration whose mission is to foster the development of new therapies to improve the lives of people living with kidney diseases. KHI has completed several projects this year, selected a new American Society of Nephrology (ASN) Co-Chair, and released a technology roadmap to outline opportunities for innovative alternatives to renal replacement therapy (RRT). Below are six highlights from the past year.